RBC Capital Downgrades Pharmacyclics (PCYC) to Sector Perform
Tweet Send to a FriendGet Alerts PCYC Hot Sheet
Price: $85.61 +0.01%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade PCYC Now!
RBC Capital downgraded Pharmacyclics (NASDAQ: PCYC) from Outperform to Sector Perform with a price target of $60.00.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $67.79 yesterday, with a 52 week range of $10.59-$68.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $67.79 yesterday, with a 52 week range of $10.59-$68.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
- Janney Montgomery Scott Downgrades Cubist Pharmaceuticals (CBST) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
